Pan-cancer analysis of whole genomes (ICGC/TCGA, Nature 2020)

Summary

Pan-cancer analysis of whole genomes (ICGC/TCGA, Nature 2020) is a study catalogued by cBioPortal DataHub under the cancer-type code mixed. EvidenceHelix groups it with multiple or not classified from the title studies and lists it in the TCGA (other releases) collection.

Study description

WGS changes cataloged in 2,583 whole-cancer genomes and their matched normal tissues across 38 tumor types. Source data from UCSC Xena (https://xenabrowser.net/datapages/?cohort=PCAWG%20(specimen%20centric)&addHub=https%3A%2F%2Fpcawg.xenahubs.net&removeHub=https%3A%2F%2Fxena.treehouse.gi.ucsc.edu%3A443) and ICGC Data Portal (https://dcc.icgc.org/releases/PCAWG/).

Text as published in the source's study metadata.

Citation & PubMed

Campbell et al. Nature 2020

Linked PubMed records: PMID 32025007

Source & licence

Metadata from cBioPortal DataHub at e1b75cd25b, available under the ODC Open Database License (ODbL) 1.0. See the Source metadata tab for every field.

Source metadata

Study identifier

pancan_pcawg_2020

Short name

PCAWG (ICGC/TCGA)

Source cancer-type code

mixed

Reference genome

not given

Source access groups

not given

Original study

View on cBioPortal

Metadata file

meta_study.txt at e1b75cd25b

Database licence

ODC Open Database License (ODbL) 1.0

Study-level metadata only (title, description, cancer-type code, citation, PubMed ids). No patient, sample, mutation or clinical data, and no publication full text, is included. Individual studies may carry their own terms; follow each study's source links before reusing its data. TCGA data are available under the Broad Institute GDAC TCGA Analysis Pipeline License; TCGA-derived records are preliminary or legacy releases.

Citations

Campbell et al. Nature 2020

• PubMed record 32025007 ↗

Citation counts are not part of the source metadata and are not shown.

Related studies

• BRAF Fusions - ARCHER Clinical Sequencing Cohort (MSK, Clin Cancer Res 2024)

  Targeted sequencing of 107 clinical cases via ARCHER to characterize the structure and impact of BRAF fusions on clinical course in a tumor-agnostic approach. This study is part of a broader analysis and is complement…

  Multiple or not classified from the titleMSK studiesSource code mixedPubMed 1

• BRAF Fusions - IMPACT Clinical Sequencing Cohort (MSK, Clin Cancer Res 2024)

  Targeted sequencing of 105 clinical cases via MSK-IMPACT to characterize the structure and impact of BRAF fusions on clinical course in a tumor-agnostic approach. This study is part of a broader analysis and is comple…

  Multiple or not classified from the titleMSK studiesSource code mixedPubMed 1

• Cancer Cell Line Encyclopedia (Broad, 2019)

  Cancer Cell Line Encyclopedia from the Broad Institute and Novartis, updated 2019. Data downloaded from the Broad CCLE Portal (https://portals.broadinstitute.org/ccle/data). For more info about the proteomics data, se…

  Multiple or not classified from the titleOther published and consortium studiesSource code mixedPubMed 2

• Cancer Cell Line Encyclopedia (Broad, Nat Rev Cancer 2025)

  Whole genome and whole exome sequencing of 1,981 pancancer samples from the Cancer Cell Line Encyclopedia (CCLE). CCLE from Broad Institute and Novartis, 2025 (25Q3) update. Data downloaded from the Depmap Portal (htt…

  Multiple or not classified from the titleOther published and consortium studiesSource code mixedPubMed 1

• Cancer Cell Line Encyclopedia (Genentech, Nat biotech 2014)

  Single-nucleotide polymorphism (SNP) array analysis and RNA sequencing and of 675 mixed human cancer cell lines from the Cancer Cell Line Encyclopedia.

  Multiple or not classified from the titleOther published and consortium studiesSource code mixedPubMed 1

• Cancer Therapy and Clonal Hematopoiesis (MSK, Blood Adv 2023)

  Targeted sequencing of 47,532 patient samples with mixed tumor types and their matched normals to identify clonal hematopoiesis mutations using MSK-IMPACT.

  Multiple or not classified from the titleMSK studiesSource code mixedPubMed 1

• Cancer Therapy and Clonal Hematopoiesis (MSK, Clin Cancer Res 2022)

  Clonal hematopoiesis mutations identified in blood samples from patients whose tumor-blood pairs were analyzed using MSK-IMPACT.

  Multiple or not classified from the titleMSK studiesSource code mixedPubMed 1

• Cancer Therapy and Clonal Hematopoiesis (MSK, Nat Genet 2020)

  Clonal hematopoiesis mutations identified in blood samples from 24,146 patients whose tumor-blood pairs were analyzed using MSK-IMPACT.

  Multiple or not classified from the titleMSK studiesSource code mixedPubMed 1

Your notes

Notes and highlights stay in this browser only; they are not sent to EvidenceHelix.